Sapropterin Dihydrochloride

盐酸沙丙蝶呤

Report date: 2025/12/30 13:35:49
NMEFirst In Class

Base Information

Drug NameSapropterin Dihydrochloride
Drug Alias Name盐酸沙普蝶呤sapropterina四氢生物蝶呤sapropterinum二盐酸沙丙蝶呤 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhenylalanine hydroxylase agonists
TargetsPhenylalanine hydroxylase
Therapy Area/IndicationsSchizophreniaAnemia, Sickle CellHypertension +[8] 
Global Approved IndicationsPhenylketonurias
Approved Indications in ChinaPhenylketonurias
Original Approved Country/TerritoryJapan
Original Approved Date1992/03/27
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiomarin Pharmaceutical IncSohag UniversityBiomarin International Ltd +[4] 
Inactive CompaniesThe Kennedy Institute-National Eye ClinicUniversity Of OxfordJohns Hopkins University +[10] 
Active IndicationsPhenylketonurias
Inactive IndicationsSchizophreniaAnemia, Sickle CellHypertension +[7] 

Other Information

ATC CodeA16AX07
Related LinksWikipediaDrugBankKEGG